Cite
HARVARD Citation
Elsby, R. et al. (2023). Mechanistic in vitro studies indicate that the clinical drug–drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3. Pharmacology research & perspectives. 11 (2), p. n/a. [Online].